top of page

Recent Posts

Aug 26, 2022

New chemical technology leads to better targeted therapeutics against high-risk leukemia in the lab

Scientists from St. Jude Children’s Research Hospital have created an LCK targeted PROTAC, demonstrating its enhanced ability to kill T-cell acute lymphoblastic leukemia cells.

Read more: https://www.stjude.org/media-resources/news-releases/2022-medicine-science-news/new-technology-leads-to-better-therapeutics-against-high-risk-leukemia.html

コメント

CNIO opens up new research pathways against paediatric cancer Ewing sarcoma by discovering mechanisms that make it more aggressive

Larotrectinib Is Promising for Pediatric TRK Fusion-Positive CNS Tumors

Researchers identify gene signature for high-risk form of T-cell acute lymphoblastic leukemia

If My Dying Daughter Could Face Her Mortality, Why Couldn’t the Rest of Us?

FDA Grants Rare Pediatric Designation to Elraglusib for Ewing Sarcoma

Self-reported screening can reduce distressing symptoms for pediatric patients with cancer

Cell therapy fights lethal childhood brain cancer in Stanford Medicine trial

Increased Surveillance Recommended for Children at Risk for Hematopoietic Malignancy Predisposition

Targeted therapy and radiation synergize in pediatric high-grade glioma

Even 15 Years Later, Childhood Cancer Survivors More Likely to Develop Leukemia

Archive

Search By Tags

bottom of page